Fabino Enterprises has posted a consolidated net loss of Rs 55.87 lakh for FY 2025-26, shifting from a profit in the previous year. Alongside the weak financial performance, the company confirmed a significant change in ownership with the R G Family Trust and associated acquirers signing an agreement to buy a 56.82% controlling stake. This has triggered an open offer for 26% of equity at Rs 20 per share. Additionally, the company is divesting its entire stake in subsidiary Upender Metaplast Private Limited for Rs 5 lakh.
Fabino Enterprises Reports FY26 Loss, Announces Promoter Transition
Consolidated Net Loss: Rs 55.87 lakh | Total Consolidated Income: Rs 2240.44 lakh
Reader Takeaway: The company faces a turnaround challenge as new promoters take control and non-core subsidiary operations are divested.
What just happened
Fabino Enterprises has reported a net loss of Rs 55.87 lakh for the fiscal year 2025-26, a reversal from the profit of Rs 6.11 lakh recorded in the prior year. Total consolidated income rose to Rs 2240.44 lakh from Rs 1832.63 lakh in FY 2024-25, yet increased costs dragged the bottom line into the red. On a standalone basis, the company reported a net loss of Rs 35.97 lakh.
Why this matters
The company is undergoing a major structural shift. On April 28, 2026, the R G Family Trust, along with Mr. Sameer Gupta and Mr. Sundeep Gupta, entered into an agreement to acquire a 56.82% stake in the firm. This acquisition triggers an open offer for 26% of the company's equity at a price of Rs 20 per share. This change in promoter control signals a potential strategic pivot for the business.
Subsidiary Divestment
Fabino Enterprises has decided to exit its investment in Upender Metaplast Private Limited. The board has approved the sale of its entire 50,000-share stake to Mr. Atul Jain and Mrs. Vandana Jain for a total consideration of Rs 5 lakh. This divestment is intended to streamline operations and focus on core business objectives.
Risks to watch
Investors should monitor the company's ability to return to profitability following the FY26 loss. The management has previously highlighted risks associated with pharmaceutical market volatility, specifically regarding supply chain fluctuations and pricing pressures, which could continue to impact margins in the coming quarters.
Governance and Operations
The company will conduct its 15th Annual General Meeting on September 29, 2026, via video conferencing. The management has confirmed that internal auditors have not raised any significant concerns regarding the firm's internal financial controls. As a BSE SME-listed entity, the company remains exempt from standard corporate governance compliance requirements.